Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | VEGFA | P15692 | 2/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29918369 | 1.00 | SOS1 (0.40) | SOS1MAOBHTR2ASLC6A4MAOA | |
| SCHEMBL14656303 | 0.85 | SOS1 (0.44) | SOS1MAOBHTR2ASLC6A4THRB | |
| SCHEMBL14667731 | 0.85 | HTR2A (0.42) | MAOBHTR2ASLC6A4MAOATHRB | |
| SCHEMBL14656099 | 0.85 | THRB (0.44) | HTR2ASLC6A4THRBRORC | |
| SCHEMBL15903973 | 0.84 | THRB (0.40) | MAOBHTR2ASLC6A4MAOATHRB | |
| SCHEMBL14656049 | 0.84 | LTA4H (0.41) | SOS1MAOBTHRBRORCLTA4H | |
| SCHEMBL14656137 | 0.82 | KIF11 (0.53) | — | |
| SCHEMBL14656157 | 0.82 | PLA2G7 (0.44) | HTR2ASLC6A4 | |
| SCHEMBL5125208 | 0.81 | LTA4H (0.57) | SOS1MAOBHTR2ASLC6A4MAOA | |
| SCHEMBL18235868 | 0.81 | HSP90AA1 (0.45) | HTR2ASLC6A4THRBRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300965-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-12 | — | — | US | disclosed |
| US-11999746-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-06-04 | — | — | US | disclosed |
| US-20230044787-A1 | TRICYCLE DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-20200055863-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-02-20 | — | — | US | disclosed |
| US-20200055863-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-02-20 | — | — | US | disclosed |
| US-10428078-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| US-10428078-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| EP-3172211-B1 | TRICYCLIC IMIDAZO-PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY LP-PLA2 | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-07-03 | — | — | EP | disclosed |
| EP-3172211-B1 | TRICYCLIC IMIDAZO-PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY LP-PLA2 | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-07-03 | — | — | EP | disclosed |
| US-20190023715-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-24 | — | — | US | disclosed |
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| EP-2739627-A1 | 2,3-DIHYDROIMIDAZO[1,2-C]PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA² INHIBITORS | Glaxo Group Limited (GB) | 2014-06-11 | — | — | EP | disclosed |
| EP-2736908-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | Glaxo Group Limited (GB) | 2014-06-04 | — | — | EP | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2013013503-A1 | 2,3-DIHYDROIMIDAZO[1,2-C] PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013014185-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013014185-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013013503-A1 | 2,3-DIHYDROIMIDAZO[1,2-C] PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055863-A1 | COMPOUNDS | PLAAT2, PLA2G12A, PLA2G1B | SOS1 4737/4885MAOB 351/4885HTR2A 1188/4885 |
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | PLA2G7, PLA2G4A, PLA2G1B | SOS1 4026/4885MAOB 356/4885HTR2A 1584/4885 |
| US-20190023715-A1 | COMPOUNDS | PLAAT2, PLA2G12A, PLA2G1B | SOS1 4737/4885MAOB 351/4885HTR2A 1188/4885 |
| US-10428078-B2 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | SOS1 4737/4885MAOB 351/4885HTR2A 1188/4885 |
| US-20230044787-A1 | TRICYCLE DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | LYPLAL1, LYPLA1, LYPLA2 | SOS1 2394/4885MAOB 924/4885HTR2A 2177/4885 |
| US-20240300965-A1 | COMPOUNDS | PLAAT2, PLA2G12A, PLA2G1B | SOS1 4737/4885MAOB 351/4885HTR2A 1188/4885 |
| US-20130030012-A1 | COMPOUNDS | LPCAT1, PLA2G7, PLAAT2 | SOS1 4415/4885MAOB 474/4885HTR2A 1815/4885 |
| US-11999746-B2 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | SOS1 4737/4885MAOB 351/4885HTR2A 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.